ŠĻą”±į>ž’ fhž’’’e’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ģ„Į5@ šæO/bjbjĻ2Ļ2 *R­X­X0'’’’’’’ˆśśśśśśśr r r 8Ŗ Ę l%@n>!>!T!T!T!T!T!T!¤?¦?¦?¦?¦?¦?¦?$“ARåCŹ?śT!T!T!T!T!Ź?śśT!T!ß?(#(#(#T!"śT!śT!¤?(#T!¤?(#(#>#6(<ąśśĢ>T!2! S>Ś¾“Är v!=ų>¬õ?0%@$=ØuD†!¢uD8Ģ>śśśśuDśĢ>,T!T!(#T!T!T!T!T!Ź?Ź?dr (#r Deep Vein Thrombosis/Pulmonary Embolism Potential DRP’s Drug interactions eg. NSAID’s and warfarin Experiencing s/sx, requires treatment Requires prophalactic treatment Risk of recurrent due to lifestyle eg. smoking Signs and Symptoms DVT Calf pain and tenderness Calf or leg swelling Erythema Leg Warmth Dilation of Superficial Veins Palpable Cord – affected vein may feel like a rope deep under the skin in the calf or thigh Homan’s sign – dorsiflexion of the foot may elicit pain behind the knee PE dyspnea, tachypnea chest pain, tachycardia, palpitations cough diaphoresis hemoptysis neck vein distension fever (low-grad) cyanosis, hypoxemia gallop rhythm hypotension, syncope oligria shock Pathophysiology VTE results from colt formation within the venous circulation. It can manifest as either DVT or PE Venous thrombi are composed almost entirely of fibrin and erythrocytes, platelets, wbc, this is a red clot. Arterial clot is just platelets so it is a white clot. Distal vs. Proximal : Distal is in the calf etc, proximal is higher up. Proximal is more dangerous because the veins are larger thus the clot would be larger. Virchow’s Triad: (1) Blood flow (2) Blood vessels (3) circulating elements in the blood – if anything abnormal is trial = clot formation. Most venous thrombi begin in the valve cusps of deep calf veins. Then they can: remain asymptomatic lyse obstruct the venous circulation propagate to more proximal veins emobolize act in any combination of the above For PE: Thrombus can go from site of origin to inferior vena cava Right ventricle pumps thrombus into pulmonary arteries where thrombus lodges Embolus obstructs pulmonary arteries and causes increase in resistance to blood flow in pulmonary vessels May lead to severe pulmonary hypertension, RV strain and cardiac heart failure Urgency DVT: Urgent – it can progress to PE very fast. Can be asymptomatic DVT and go to symptomatic PE. PE: URGENT – 30% mortality and 8% even if treated Causes VTE is uncommon in the absense of risk factors and the effect of the risk factors is additive D/Dx Cellulitis MI Diagnosis DVT venography gold standard high cost nephrotoxic contrast medium/ invasive procedure possible induction of VTE ultrasonography insensitivity for small thrombi and most distal DVTs noninvasive Ultrasound imaging (Doppler) is now the first investigation of choice for proximal (popliteal or femoral) vein thrombosis, although venography retains a key role in cases of suspected calf vein thrombosis (where ultrasound is relatively insensitive) or recurrent disease PE pulmonary angiography gold standard high cost nephrotoxic contrast medium/ invasive procedure possible induction of VTE ventilation/perfusion (VQ) scan less sensitive but less invasive Risk Factors: Age Males Venous Stasis (Major Medical Illness (CHF, MI), major surgery, immobility after surgery, paralysis, polycythemia vera (high blood viscosity), obesity, varicose veins Vascular Injury (Major orthopedic surgery (knee/hip replacement), trauma, in-dwelling venous catheter) Hypercoagulable state – malignancies, activated protein C resistance/factor V Leiden, Prothrombin (20210A) gene mutation, protein C deficiency, protein S deficiency, Antithrombin deficiency, Factor VIII excess, Factor XI excess, Antiphospholipid antibodies, disfibrinogemia, hyperhomocysteinemia, plasminogen activator inhibitor excess nephritic sydrome Pregnancy/post-partum Any of drugs listed below Drugs Causing Similar S&S Estrogen-containing oral contraceptive pills Estrogen replacement therapy Selective estrogen receptor modulators (SERMs) estrogens increase serum clotting factor concentrations and induce activated protein C resistance...thus the increased risk of VTE observed during pregnancy and the immediate postpartum period risk of DVT especially high if smoking on OTC and patient is >30 yrs Heparin-induced thrombocytopenia (HIT) Nonpharmacological Options Elevate leg Compression stockings No standing or sitting for long periods of time No crossing of legs No restrictive clothing Pharmacological Options Unfractionated Heparin Along with LMWH, mainstay of acute treatment of VTEs Composed of glycosoaminoglycans of various lengths Onset: 1-2 hours (IV immediate onset) SEs: bleeding, local irritation, mild pain, erythemia, Heparin Induced Thrombocytopenia, Contraindications: active bleeding, hemophilia, hemorrhagic tendencies, severe liver disease DIs: Antithrombolytics and antiplatelets increase risk of bleeding Low bioavailability, therefore have to give parenterally – IV better b/c more predictable Drug itself is cheap but overall costs more than LMWH due to monitoring needed LMWH (ardeparin, dalteparin, enoxaparin, nadroparin, tinzaparin) Also mainstay of treatment Longer halflife (2-4 times longer than UFH), better bioavailability Peak anticoagulation at 3-5 hours Similar SEs, Contraindications and DIs to UFH Less bleeding than UFH Accumulates in renal impairment Can be given SC q12-24h Relatively expensive Heparanoid (Danaparoid) Inhibits thrombin generation by an effect on Xa Peak Effect in 5 hours but 4-5 days before steady state SEs: Bleeding, bruising Can be used in pregnancy but only if UFH or LMWH is contraindicated Accumulates in renal impairment More expensive than LMWH Anti-factor Xa inhibitor (Fondaparinux-indirect inhibitor) Bind Xa Fondaparinux approved in prevention of VTE following lower extremity orthopedic procedures (2.5 mg SC q12h) Hidrudin and Direct Thrombin Inhibitors (Agratroban, Lepirudin, Ximelagatran) Inhibit thrombin activity directly (both circulating and clot bound thrombin) Used in prevention of VTE and in HIT Onset: Immediate SEs: Hemorhage, minor bleeding, small decrease in RBC count, fever, N/V, allergic rxn DIs: Increased risk of bleeding with other antithrombolytics and antiplatelets lepirudin and argatroban should be used cautiously in women of child-bearing age b/c experience is limited Warfarin Approved for prevention and treatment of VTEs Inhibits the enzyme responsible for cyclic conversion of vit K (inhibits synthesis of factors II, VII, IX, X) S isomer 2-5 times more potent but is racemic mixture Full effect not seen until 8-16 days after therapy initiated (due to long half-lives of some of the factors) SEs: bleeding especially GI bleeding, purple toe syndrome, skin necrosis (rare) LOTS OF DIs: b/c metabolized by CYP 450 including 1A2, 2C9, 3A4 CI: active bleeding, hemorrhagic tendencies, PREGNANCY, history of warfarin-induced skin necrosis Dosing is about 30-40 mg/week (divided into daily doses) but lower dose in patients >65 years, elevated INRs, poor nutritional status, liver disease CHEAP THROMBOLYTIC THERAPY Streptokinase Activates plasminogen, dissolves fibrin, degrades fibrinogen For treatment of SEVERE or life-threatening VTEs Onset: Immediate Contraindicated: active bleeding, recent surgery, stroke or severe trauma, recent streptococcal infection or hypersensitivity Given IV, Expensive Urokinase Same effect as Streptokinase Immediate onset CIs: active bleeding, recent surgery, any hemorrhagic disease Given IV Alteplase (Tissue Plasminogen Activator), Reteplase Activates plasminogen bound to fibrin, dissolves fibrin Treatment of severe or life-threatening VTEs Immediate onset CIs same as Urokinase Given IV Expensive MANAGEMENT Start on LMWH LMWH (compared to UFH) has more predictable kinetics and doesn’t require monitoring, less risk of major bleeding, can be used on an outpatient basis, longer duration of activity, doesn’t need daily INR (could be started on day 3) BUT expensive (5 days of therapy ~$80), No major clinical differences among the types of LMWH – pt’s standpoint would want once daily dosing – FRAGMIN (daltaparene) – used more than others Start also on warfarin – initially as well – start with 10 mg/daily, monitor INR Warfarin dose requirements – dose DECREASES with age <30 – may need up to 10 mg >80 – average is 3 mg/day No good evidence that loading doses work – b/c no difference in factor II decline (longest half-life) BUT they are still used with the rationale that INRs normalize quickly and can get them off Fragmin sooner Want INR between 2-3 and then d/c daltaparene Get INR around day 3 – b/c INR can decrease fast with decrease in factor 7 (even though factor 2 may still be high) therefore should wait few days for INR Counseling on warfarin: Internal bleeding Bad headache – may be CNS intracranial bleed If worst headache – go to ER If pain – ie. ab – perineal, go to ER BUT make sure not to alarm pt and say risk is < 1% Have blood monitored regularly – INRs Poor compliance is in younger pts – need to emphasize to them No ASA or NSAIDs (unless already on it before adding warfarin) Echinecea and Gingko – cause blood thinning – if they really want to take it, take INR shortly (wait 5 days before next INR) – but definitely start by discouraging use – if they do use it, make sure they keep it consistent (same with diet – keep it steady) Clinical Outcomes Eliminate the DVT Prevent progression to PE Prevent recurrent DVT Pharmacotherapeutic Outcome The patient receives the anticoagulation medication in the right dose, duration, frequency, route, with no intolerable side effects or clinically significant drug interactions P.T. Endpoints PainImprove/Eliminate 1-2 days/2-3 daysSwelling““ClotEliminate1 day TPE Postiive No recurrent DVT while on treatment (eg. Swelling or any other s/sx Warfarin target level INR in the 2.5-3 range Negative No abnormal bleeding anytime during treatment No decrease in platelets No skin reactions. (very rare s/e) MONITORING INR should be done every 2-3 days after initiation of therapy until target levels reached and gradually decrease Also monitor for headaches, excessive bleeding When to go the ER: SOB, chest pain, coughing bld, black tarry stools, severe HA of sudden onset, slurred speech –could be DVT/PE or cerebral hemorrhage (stroke) SEE WEBSITE FOR COUNSELLING INFO FOR WARFARIN AND POTENTIAL DRUG INTERACTIONS -  PAGE 1 - )*:Ūö ł ŗ » Ė Ļ % ) , . / š › Ń Ņ q ż N ²  '(ŗ»Ā!%&345?CN±ĮōźŚźÖĻÖźÖōÄōÄōÄÖ¼Ö¼Ö·ÖźÖźŚŖźÖźŖź€źrkźÖźÖ h¾ *\]h¾ *56>*CJOJQJh »h¾ *CJOJQJh »h¾ *5>*CJOJQJh—QŽh¾ *CJOJQJh¾ *5>*CJOJQJ h¾ *\h—QŽh¾ *\h¾ *CJOJQJ\ h¾ *5\h¾ *h—QŽh¾ *5>*CJOJQJh¾ *CJOJQJh¾ *5CJOJQJ*()*:e‹«ŚŪīņ öš•••ˆƒo & F ĘŠ„h„L’^„h`„L’gd¾ *gd¾ *gd¾ * & F gd¾ *gd¾ *[kd$$If–lÖ””Ö”’¬Ö0’’’’’’öÖ’Ö’Ö’Ö’4Ö laö $Ifgd¾ * 0/N/żż ) 4 R ® ö ł 2 8 D O d u ‰ — ¬ “ ŗ » Ė / › Ņ r ėėėėėėęėėėėėėėėėėėėįÜįėėėgd¾ *gd¾ *gd¾ * & F ĘŠ„h„L’^„h`„L’gd¾ *r ż N b g ‡ Ø ² Ö Ž eĻ (‰»Ā !&ėėćććććŪėŪŪŪŪÖÖÖÖÖŃ½ÖÖ & F Ę8„h„˜ž^„h`„˜žgd¾ *gd¾ *gd¾ * & Fgd¾ * & Fgd¾ * & F ĘŠ„h„L’^„h`„L’gd¾ *&145?CN\g—±Įö+9CtŽśśśśõķŁŁŁŁķŁŁŌõĢļ“¬ & F gd¾ * & Fgd¾ * & Fgd¾ * & Fgd¾ * & Fgd¾ *gd¾ * & F ĘŠ„h„L’^„h`„L’gd¾ * & Fgd¾ *gd¾ *gd¾ *ĪĻŠŻŽ‡ˆ¢IdćūC„—Ƭē\Ŗ>G")"£$¤$²$V&Ø&ć'Ä(+/+0+s++@,O,’-“-ž-//0/?/öėöēŻēŻĢĮēŻŗē“ŻēŻēŻēŻēŻēŻēŻē­ē­ŻēŻēŻē£œē’ē’ē‹­ē‡}h¾ *CJOJQJhėRE h°X‰h¾ *h°X‰h¾ *5>* h¾ *5>*h »h¾ *5>* h¾ *5\ h¾ *^J h¾ *6>*h¾ *>*CJOJQJ!h¾ *56>*CJOJQJ\]h¾ *CJOJQJh¾ *h »h¾ *6\]h¾ *56\]1Ž®ĻŠŽāčŽõWm‡ˆ¢ĻģÜ!HIdp÷ļźźÖÖÖÖÖÖÖźŃÖÖÖÖÖÖČĆļgd¾ *„“^„“gd¾ *gd¾ * & F ĘŠ„h„L’^„h`„L’gd¾ *gd¾ * & Fgd¾ * & Fgd¾ *p†¶ŹāćūGz śWšōC„Ÿć3Jj‚—÷÷÷÷ņķåŃŃŃŃŃŃŃŃåŃŃŃŃŃŃŃŃ & F ĘŠ„h„L’^„h`„L’gd¾ * & Fgd¾ *gd¾ *gd¾ * & Fgd¾ *—Æß/s“¬ēš\Ŗų.„Ó>Guć † Ö !x! "÷ćććććć÷ćć÷ćććććć÷ćććććććć & F ĘŠ„h„L’^„h`„L’gd¾ * & Fgd¾ * """)"7"t"„"¶"4#H#R#o##½#Ę#ś#2$_$o$…$Ž$˜$™$¤$²$ėęęŽėėėėėŽėėėėŽėėėėėėęŁŃ & F gd¾ *gd¾ * & Fgd¾ *gd¾ * & F ĘŠ„h„L’^„h`„L’gd¾ *²$Į%V&Ø&Ż&ų&'ć'(¬(Ä(Ö() )F)y)Ÿ)Ż)*++0+B+\+r+s+ėėćėėėėćććėėėėėėėėėŚŚŚŚŚŚ„“^„“gd¾ * & F gd¾ * & F ĘŠ„h„L’^„h`„L’gd¾ *s++?,@,O,T,g,y,z,ƒ,ööööķķķbķ‹kdŽ$$If–lÖÖF”’œ¤ ¬ tąÖ0’’’’’’ö6öÖ ’’’Ö ’’’Ö ’’’Ö ’’’4Ö4Ö laö $Ifgd¾ *„“^„“gd¾ * ƒ,…,‡,ˆ,,—,,óóh___ $Ifgd¾ *‹kdā$$If–lÖÖF”’œ¤ ¬ tąÖ0’’’’’’ö6öÖ ’’’Ö ’’’Ö ’’’Ö ’’’4Ö4Ö laö $$Ifa$gd¾ *,ž, ,­,ń,--(-V-o-’-“-ž-tkkkkkkkkkkk„“^„“gd¾ *‹kd6$$If–lÖÖF”’œ¤ ¬ tąÖ0’’’’’’ö6öÖ ’’’Ö ’’’Ö ’’’Ö ’’’4Ö4Ö laö ž-.>.ß.ą.//0/L/M/N/O/ėėėęęäāääägd¾ * & F ĘŠ„h„L’^„h`„L’gd¾ * ?/@/F/G/H/I/L/N/O/ńēńŲńēŌŠhėREh¾ *h¾ *CJOJQJmHnHuh¾ *CJOJQJjh¾ *CJOJQJU(1h°Š/ °ą=!°Š"°Š#Š$`%° P °Œ$$If–!vh5Ö#v:V –l””Ö0’’’’’’öö5Ö/Ö ’4ÖR$$If–!vh5Ö5Ö5Ö#v:V–l tąö65ÖR$$If–!vh5Ö5Ö5Ö#v:V–l tąö65ÖR$$If–!vh5Ö5Ö5Ö#v:V–l tąö65Öœ@`ń’@ ¾ *NormalCJ_HaJmH sH tH P`P ¾ * Heading 1$@&56CJOJQJ\]^JT`T ¾ * Heading 2$@&56>*CJOJQJ\]^JF`F ¾ * Heading 3$@&5CJOJQJ\DAņ’”D Default Paragraph FontRi@ó’³R  Table Normalö4Ö l4Öaö (kō’Į(No List:B`ņ: ¾ * Body Text CJOJQJ4 `4 ¾ *Footer  ĘąĄ!jš`³j ¾ * Table Grid7:VÖ0’’’’’’O' R’’’’()*:e‹«ŚŪīņ  )4R®öł 28DOdu‰—¬“ŗ»Ė/›ŅrżNbg‡Ø²ÖŽeĻ (‰»Ā !&145?CN\g—±Įö   + 9 C t Ž ® Ļ Š Ž ā č Ž õ W m ‡ ˆ ¢ Ļ ģ Ü!HIdp†¶ŹāćūGz śWšōC„Ÿć3Jj‚—Æß/s“¬ēš\Ŗų.„Ó>Guć†Öx )7t„¶4HRo½Ęś2_o…Ž˜™¤²ĮVØŻųć ¬ Ä Ö ! !F!y!Ÿ!Ż!"##0#B#\#r#s##?$@$O$T$g$y$z$ƒ$…$‡$ˆ$$—$$ž$ $­$ń$%%(%V%o%’%“%ž%&>&ß&ą&/'0'L'P'©0€€ ™0€€ ˜0€€€˜0€€€˜ 0€€€˜ 0€€€˜ 0€€€˜ 0€€€˜0€€€0€€€(0€Ū€˜ 0€ī€˜ 0€ī˜ 0€ī€˜ 0€ī€˜ 0€ī€˜ 0€ī€˜ 0€ī€˜0€ī€˜ 0€ī€˜ 0€ī€˜ 0 €ī€˜ 0 €ī€˜ 0 €ī€˜ 0 €ī€˜ 0 €ī€˜ 0€ī€˜ 0€ī€˜ 0€ī€˜ 0€ī€˜ 0€ī€˜0€ī€0€€€˜0€»€˜ 0€»€˜ 0€»€˜ 0€»€˜ 0€»€˜ 0€»€˜ 0ż»€˜ 0ż»€˜ 0ż»€˜ 0ż»€˜ 0ż»€˜ 0ż»€˜ 0€»€˜ 0Ö»€˜ 0Ö»€˜ 0Ö»€˜ 0Ö»€˜0€»€˜0€»€˜0€»€˜0€»€˜0€»€0€€€˜ 0€»€˜0€»€˜0€»€˜0€»€˜0€»€˜0€»€˜0€»€(0€»€˜ 0€?€˜ 0€?€˜ 0€?€˜ 0€?€˜ 0€?€˜ 0€?€˜ 0€?€˜ 0€?€0€€€(0€ €˜ 0€ €˜ 0€ €˜ 0€ ˜ 0€ ˜ 0€ ˜ 0€ ˜ 0€ €˜0€ €˜0€ €˜ 0€ €˜ 0 € €˜ 0!€ €˜ 0"€ €˜ 0#€ €˜ 0$€ €˜ 0%€ €˜0€ €(0€ €˜ 0&€ˆ €˜ 0'€ˆ €˜ 0(€ˆ €˜ 0)€ˆ €˜ 0*€ˆ €˜ 0+€ˆ €˜0€ˆ €0€ €˜ 0€I€˜ 0€I€˜ 0€I€˜ 0€I€˜ 0€I€˜0€I€0€ €˜ 0€ć€˜ 0,€ć€˜ 0-€ć€˜ 0.€ć€˜ 0/€ć€˜ 00€ć€˜ 01€ć€˜ 02€ć€˜ 03€ć€˜ 0€ć€˜ 04€ć€˜ 05€ć€˜ 06€ć€˜ 07€ć€˜ 08€ć€˜ 09€ć€˜ 0:€ć€˜ 0;€ć€˜ 0€ć€˜ 0<€ć€˜ 0=€ć€˜ 0>€ć€˜ 0?€ć€˜ 0@€ć€˜ 0A€ć€˜ 0€ć€˜ 0B€ć€˜ 0C€ć€˜ 0€ć€˜ 0D€ć€˜ 0E€ć€˜ 0F€ć€˜ 0G€ć€˜ 0H€ć€˜ 0I€ć€˜ 0€ć€˜ 0J€ć€˜ 0K€ć€˜ 0L€ć€˜ 0M€ć€˜ 0N€ć€˜ 0O€ć€˜ 0P€ć€˜ 0Q€ć€˜ 0R€ć€˜0€ć€˜0€ć€˜ 0€ć€˜ 0S€ć€˜ 0T€ć€˜ 0U€ć€˜ 0V€ć€˜ 0W€ć€˜ 0€ć€˜ 0X€ć€˜ 0Y€ć€˜ 0Z€ć€˜ 0[€ć€˜ 0€ć€˜ 0\€ć€˜ 0]€ć€˜ 0^€ć€˜ 0_€ć€˜ 0`€ć€˜ 0a€ć€˜0€ć€0€€€˜ 0€™€˜ 0b€™€˜ 0c€™€˜ 0€™€˜ 0d€™€˜ 0e€™€˜ 0f€™€˜ 0g€™€˜ 0€™€˜ 0€™€˜ 0€™€˜@ 0h€™˜@ 0i€™˜@ 0j€™˜@ 0k€™˜@ 0l€™˜@ 0m€™˜@ 0n€™˜@ 0o€™˜@ 0p€™˜@0€™ ˜@0€™ ˜@0€™ ˜@0€™ ˜@0€™ ˜@0€™ ˜@0€™p˜@0€™ ˜@0€™p˜@0€™©@0€™ ©@0€™ ©@0€™ ™@0€™ ©@0€™ ©@0€™ ©@0€™ ™@0€™ ©@0€™ ©@0€™ ©@0€™ ™@0€™ ˜@0€™ų€˜@0€™ ˜@0€™p˜@0€™ ˜@0€™p˜@0€™p˜@0€™˜@0€™p˜@0€™˜@0€™€˜@0€™˜@ 0q€™˜@ 0r€™˜@ 0s€™ˆ˜@0€€p˜@0€€My00€˜@0€€ų€0ŗ¼o7 ?/O/( r &Žp— "²$s+ƒ,,ž-O/ !"#$%&'N/ !’•€/'0'?'I'P'/'P'*:e«ŪRöĖ?²ÖŽ»ĀCĮö  č W ģ !†¶„Ÿć3j‚Æ/s¬ēš.>G 7„¶4½ś_²Ż¬ Ö y!Ÿ!@$­$‚%ž%0'4'K'M'P'’’Andria #>^®xŗż’’’’’’’’’Ā`ŻbׂŸ’’’’’’’’’±l p„Ņ’’’’’’’’’y®xŗż’’’’’’’’’Jjü!3ĪĪ’’’’’’’’’tK”%,y”’’’’’’’’’\y¾*Ģš¼Ć’’’’’’’’’}IO9–Z¢ė’’’’’’’’’ä0¾B®xŗż’’’’’’’’’VzCH®xŗż’’’’’’’’’V’b®xŗż’’’’’’’’’h„@„ąžĘˆ^„@`„ąžOJPJQJ^Jo(-h„X„˜žĘX^„X`„˜ž.’h„(„L’Ę(^„(`„L’.h„ų „˜žĘų ^„ų `„˜ž.h„Č „˜žĘČ ^„Č `„˜ž.’h„˜„L’Ę˜^„˜`„L’.h„h„˜žĘh^„h`„˜ž.h„8„˜žĘ8^„8`„˜ž.’h„„L’Ę^„`„L’.h„°„PžĘ°^„°`„Pžo(.h„8„˜žĘ8^„8`„˜ž.’h„„L’Ę^„`„L’.h„Ų „˜žĘŲ ^„Ų `„˜ž.h„Ø „˜žĘØ ^„Ø `„˜ž.’h„x„L’Ęx^„x`„L’.h„H„˜žĘH^„H`„˜ž.h„„˜žĘ^„`„˜ž.’h„č„L’Ęč^„č`„L’.„Š„˜žĘŠ^„Š`„˜žOJPJQJ^Jo(-h„ „˜žĘ ^„ `„˜ž.Ų„(„ąžĘp^„(`„ąžOJPJQJ^Jo(-€ „@ „˜žĘ@ ^„@ `„˜žOJQJo(·š€ „„˜žĘ^„`„˜žOJQJo(o€ „ą„˜žĘą^„ą`„˜žOJQJo(§š€ „°„˜žĘ°^„°`„˜žOJQJo(·š€ „€„˜žĘ€^„€`„˜žOJQJo(o€ „P„˜žĘP^„P`„˜žOJQJo(§šh„@„ąžĘˆ^„@`„ąžOJPJQJ^Jo(-h„X„˜žĘX^„X`„˜ž.’h„(„L’Ę(^„(`„L’.h„ų „˜žĘų ^„ų `„˜ž.h„Č „˜žĘČ ^„Č `„˜ž.’h„˜„L’Ę˜^„˜`„L’.h„h„˜žĘh^„h`„˜ž.h„8„˜žĘ8^„8`„˜ž.’h„„L’Ę^„`„L’.„Š„˜žĘŠ^„Š`„˜žo()€ „ „˜žĘ ^„ `„˜ž‡hˆH.‚ „p„L’Ęp^„p`„L’‡hˆH.€ „@ „˜žĘ@ ^„@ `„˜ž‡hˆH.€ „„˜žĘ^„`„˜ž‡hˆH.‚ „ą„L’Ęą^„ą`„L’‡hˆH.€ „°„˜žĘ°^„°`„˜ž‡hˆH.€ „€„˜žĘ€^„€`„˜ž‡hˆH.‚ „P„L’ĘP^„P`„L’‡hˆH.„8„0żĘ8^„8`„0żo(.h„ „˜žĘ ^„ `„˜ž.‚„p„L’Ęp^„p`„L’.€„@ „˜žĘ@ ^„@ `„˜ž.€„„˜žĘ^„`„˜ž.‚„ą„L’Ęą^„ą`„L’.€„°„˜žĘ°^„°`„˜ž.€„€„˜žĘ€^„€`„˜ž.‚„P„L’ĘP^„P`„L’.„°„PžĘ°^„°`„Pžo(. „ „˜žĘ ^„ `„˜žOJQJo(o „p„˜žĘp^„p`„˜žOJQJo(§š „@ „˜žĘ@ ^„@ `„˜žOJQJo(·š „„˜žĘ^„`„˜žOJQJo(o „ą„˜žĘą^„ą`„˜žOJQJo(§š „°„˜žĘ°^„°`„˜žOJQJo(·š „€„˜žĘ€^„€`„˜žOJQJo(o „P„˜žĘP^„P`„˜žOJQJo(§šh„°„PžĘ°^„°`„Pžo(.h„8„˜žĘ8^„8`„˜ž.’h„„L’Ę^„`„L’.h„Ų „˜žĘŲ ^„Ų `„˜ž.h„Ø „˜žĘØ ^„Ø `„˜ž.’h„x„L’Ęx^„x`„L’.h„H„˜žĘH^„H`„˜ž.h„„˜žĘ^„`„˜ž.’h„č„L’Ęč^„č`„L’.h„@„ąžĘˆ^„@`„ąžOJPJQJ^Jo(-h„X„˜žĘX^„X`„˜ž.’h„(„L’Ę(^„(`„L’.h„ų „˜žĘų ^„ų `„˜ž.h„Č „˜žĘČ ^„Č `„˜ž.’h„˜„L’Ę˜^„˜`„L’.h„h„˜žĘh^„h`„˜ž.h„8„˜žĘ8^„8`„˜ž.’h„„L’Ę^„`„L’.h„°„PžĘ°^„°`„Pžo(.h„8„˜žĘ8^„8`„˜ž.’h„„L’Ę^„`„L’.h„Ų „˜žĘŲ ^„Ų `„˜ž.h„Ø „˜žĘØ ^„Ø `„˜ž.’h„x„L’Ęx^„x`„L’.h„H„˜žĘH^„H`„˜ž.h„„˜žĘ^„`„˜ž.’h„č„L’Ęč^„č`„L’.h„@„ąžĘˆ^„@`„ąžOJPJQJ^Jo(-h„X„˜žĘX^„X`„˜ž.’h„(„L’Ę(^„(`„L’.h„ų „˜žĘų ^„ų `„˜ž.h„Č „˜žĘČ ^„Č `„˜ž.’h„˜„L’Ę˜^„˜`„L’.h„h„˜žĘh^„h`„˜ž.h„8„˜žĘ8^„8`„˜ž.’h„„L’Ę^„`„L’. ±l tK”%Ā`Ż}IO9VzCHyä0¾BV’b#>^\y¾*Jjü!’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ ’’ Ī?Žƒ        2(ŗŗ        ’’’’ Ī?Žƒ’’’’’’’’’’’’’’’’’’’’’’’’Ī?Žƒ                 ’’’’ ’’’’’’’’’’’’’’’’’’’’’’’’’’’’2(ŗŗ        2(ŗŗ        Ī?Žƒ        2(ŗŗ        Ī?Žƒ        å¾ *ėRE_P„\¬Ņ ź()\#?$@$O$T$g$y$z$ƒ$…$‡$ˆ$$—$$ž$0'M'P'–žž–’@€uuČ ¼ššuuœ¤ O'@’’Unknown’’’’’’’’’’’’G‡z €’Times New Roman5€Symbol3& ‡z €’Arial;& ‡z €’Helvetica?5 ‡z €’Courier New;€Wingdings"1ˆšŠhŠ&Š&ŁW!GŁW!G‰3šŠŠ»“‚4''3ƒQšH š’?ä’’’’’’’’’’’’’’’’’’’’’Ņ ź’’'Deep Vein Thrombosis/Pulmonary EmbolismAndriaAndria8         ž’ą…ŸņłOh«‘+'³Ł0ˆ˜ČŌäšü  ( D P \hpx€ä(Deep Vein Thrombosis/Pulmonary EmbolismeepAndriaindrndrNormaliAndriai1drMicrosoft Word 10.0@FĆ#@¾7²¾“Ä@ūÕ¾“ÄŁW!ž’ÕĶ՜.“—+,ł®0 hp€ˆ˜  Ø°ø Ą ōäHomeiG'A (Deep Vein Thrombosis/Pulmonary Embolism Title  !"#$%&'()ž’’’+,-./01ž’’’3456789:;<=>?@ABCDEFGHIJKLMNOPQRSTž’’’VWXYZ[\ž’’’^_`abcdž’’’ż’’’gž’’’ž’’’ž’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’Root Entry’’’’’’’’ ĄF0…^Ś¾“Äi€Data ’’’’’’’’’’’’*1Table’’’’2­DWordDocument’’’’*RSummaryInformation(’’’’’’’’’’’’UDocumentSummaryInformation8’’’’’’’’]CompObj’’’’’’’’’’’’j’’’’’’’’’’’’ž’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ž’ ’’’’ ĄFMicrosoft Word Document MSWordDocWord.Document.8ō9²q